Previous 10 | Next 10 |
Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. Shanghai Junshi Bio completed its $50 million investment into its US partner, Coherus BioSciences. Tianjin CanSino Biologics will start a clinical trial of an inhaled COVID-19 va...
Zai Lab (ZLAB) has priced its public offering of ~4.8M ADSs, each representing one ordinary share of the Company, at $150.00/ADS, and 224K ordinary shares, at HK$1164.20/ordinary share. Expected gross proceed are ~$750M.Underwriters' over-allotment is an additional 716.4K ADSs.The underwriter...
SHANGHAI and SAN FRANCISCO, April 20, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB, HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,7...
Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...
Gainers: [[GIFI]] +11.4%. [[SCOR]] +5.5%. [[AVNW]] +5.2%. [[NARI]] +4.6%. [[NTES]] +4.2%.Losers: [[CTLP]] -7.8%. [[FUTU]] -5.8%. [[ZLAB]] -5.7%. [[EVK]] -5.4%. [[CATB]] -3.3%. For further details see: GIFI, SCOR, CTLP and FUTU among after-hours movers
Zai Lab (ZLAB) announces public offering of $750M of ADSs, each representing one ordinary share of the company.Underwriters will be granted a 30-day option to purchase additional ADSs.The company notes "the offering is subject to market and other conditions, and there can be no assurance...
Yesterday, NovoCure ([[NVCR]] -5.2%) and its partner Zai Lab ([[ZLAB]] +2.7%) announced that a data monitoring committee (“DMC”) has recommended a reduced duration and sample size for its Phase 3 trial for Tumor Trial Fields (“TTF”) treatment in non-small cell...
Today Zai Lab ([[ZLAB]] +16.4%) and Novocure jointly announced an update to the LUNAR pivotal phase 3 trial for Tumor Trial Fields treatment in non-small cell lung cancer.Following an interim analysis of results, a data monitoring committee has recommended the trial to proceed with a red...
Gainers: Mackinac Financial (MFNC) +56%.NovoCure (NVCR) +42%.vTv Therapeutics (VTVT) +42%.Digimarc (DMRC) +20%.PLBY Group (PLBY) +20%.Ballantyne Strong (BTN) +20%.Birks Group (BGI) +18%.Zai Lab (ZLAB) +16%.B. Riley Financial (RILY) +15%.Nam Tai Property (NTP) +14%.Losers: Brook...
Gainers: NovoCure (NVCR) +45%, vTv Therapeutics (VTVT) +28%, Rigel Pharmaceuticals (RIGL) +15%, Zai Lab (ZLAB) +14%, Vallon Pharmaceuticals (VLON) +10%.Losers: Avenue Therapeutics (ATXI) -17%, AdaptHealth (AHCO) -17%, Brook...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...